Pharmacist-Led Cardiovascular Risk Service for Reducing Heart Disease Risk
(CVRSLive Trial)

Recruiting in Palo Alto (17 mi)

+13 other locations

Overseen byKorey Kennelty, PharmD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Korey Kennelty

No Placebo Group

Trial Summary

What is the purpose of this trial?The objective of this study is to evaluate the implementation of of a remote, pharmacist-led cardiovascular risk service (CVRS) in 12 large, organizationally and culturally diverse hospitals and health-systems, many with high proportions of minority and underserved patients.

Eligibility Criteria

This trial is for English or Spanish speakers who have visited the clinic in the past year and are currently managing diabetes with an HA1c of 9.0%+ or high blood pressure with a systolic reading of 150 mm Hg+. It's not open to those unable to consent, living in nursing homes, without a phone, diagnosed with short-term cancer prognosis, pregnant women, dementia patients, or planning to leave the clinic soon.

Inclusion Criteria

I speak English or Spanish.

I have diabetes with an HA1c of 9.0% or higher, or I have hypertension with a systolic blood pressure of 150 mm Hg or higher.

Participants who are involved in the study.

+1 more

Exclusion Criteria

Pregnancy

I am unable to understand and give consent for treatment.

You plan to stop getting treatment at the clinic within the next 24 months.

+4 more

Participant Groups

The study is testing a remote cardiovascular risk service led by pharmacists across diverse hospitals. The aim is to see how well this service can be implemented in different settings and its effectiveness for patients with high blood pressure and diabetes.

2Treatment groups

Experimental Treatment

Group I: CVRS Early InterventionExperimental Treatment1 Intervention

Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.

Group II: CVRS Delayed InterventionExperimental Treatment1 Intervention

Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.